DURHAM, N.C. / Aug 17, 2023 / Business Wire / Zoetis, the world’s leading animal health company, is pleased to invite members of the media to attend a ribbon-cutting event to mark the official opening of a new building dedicated to diagnostics and biodevices research and development (R&D) to meet the needs of veterinarians, livestock farmers and pet owners. The expanded site will serve as the hub for Zoetis’ engineering and diagnostics work including device reliability testing. The new building features more than 78,000 square feet including 23,000 square feet of total lab space allotted for a biodevice engineering lab, biodevice science lab, diagnostics engineering lab and diagnostics engineering lab space. Zoetis employs approximately 200 people at its site in Durham, more than half of whom are dedicated to the company’s R&D work.
The event will take place on August 24 at 11:00 AM ET at the following location:
Zoetis
1050 Swabia Court
Durham, NC 27703
During the outdoor ceremony, North Carolina State Representative Zack Hawkins and key company leaders, including Zoetis CEO Kristin Peck and President of Research and Development Rob Polzer, will be present to share insights into the new facility, potential impact on animal health and what the expansion brings to the local Durham community.
The program for the event includes:
Registration information:
Please register to attend by emailing: This email address is being protected from spambots. You need JavaScript enabled to view it..
We kindly request that media representatives check in and present press credentials at site security upon arrival.
A press release with event details and additional images will be available following the live event.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.1 billion in 2022 with approximately 13,800 employees. For more information, visit www.zoetis.com.
Last Trade: | US$176.96 |
Daily Change: | 0.25 0.14 |
Daily Volume: | 1,754,854 |
Market Cap: | US$79.840B |
November 04, 2024 September 26, 2024 August 06, 2024 May 02, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB